RESEARCH · RETATRUTIDE · SAFETY & TOLERABILITY
Retatrutide Safety and Tolerability in Published Trials: Gastrointestinal Events, Heart Rate, Escalation Design and Open Questions
PurixLab’s Retatrutide 10mg is a research vial of a single peptide with agonist activity at the GIP, GLP-1 and glucagon receptors. Our earlier articles cover the phase 1–3 clinical trial series, its pharmacokinetics and half-life and the glucagon-receptor and liver research. This article looks at the other side of the ledger: what published trials report about adverse events, how escalation design was used to manage them, and what the record cannot yet tell us. The material is supplied for laboratory research use only, and nothing here describes effects of any PurixLab product or is guidance for human use.
Tolerability as a design question from the start
The discovery paper reported that, in a phase 1 single-ascending study, the molecule showed a safety and tolerability profile similar to other incretins [1]. The 12-week phase 1b trial in 72 adults with type 2 diabetes made safety and tolerability its primary outcome. Treatment-emergent adverse events were reported by 63% of participants on retatrutide, 60% on the dulaglutide comparator and 54% on placebo, with gastrointestinal disorders the most frequent; the two highest cohorts were reached through stepwise escalation, and 29 participants discontinued the study prematurely [2].
Phase 2: side effects mapped against escalation
The phase 2 obesity trial stated that the relationships between treatment level and side effects, safety and efficacy were not known, and randomised 338 adults to placebo or several maintenance levels, some reached from different starting steps. The most common adverse events were gastrointestinal; they rose with treatment level, were mostly mild to moderate, and were partially mitigated by a lower starting step. Increases in heart rate also rose with treatment level, peaked at 24 weeks and declined thereafter [3].
The companion phase 2 trial in type 2 diabetes compared slow and fast escalation arms directly. Mild-to-moderate gastrointestinal events, including nausea, diarrhoea, vomiting and constipation, were reported in 35% of participants in the retatrutide groups, ranging from 13% in the lowest arm to 50% in a fast-escalation arm, against 13% with placebo and 35% with dulaglutide. There was no severe hypoglycaemia and no deaths, and 79% of participants completed study treatment [4]. The highest rate belongs to a fast-escalation arm rather than the arm with the highest maintenance level: the schedule, not only the level, shapes tolerability.
Phase 3: larger numbers and new signals
In the 40-week TRANSCEND-T2D-1 monotherapy trial (537 participants), the most frequent adverse events were generally mild to moderate gastrointestinal events that subsided over time. Discontinuations due to adverse events were 2-5% with retatrutide and 0% with placebo, no severe hypoglycaemia was reported, and two deaths, both judged unrelated to the study drug, occurred in one retatrutide group [5].
The 80-week TRIUMPH-2 trial in 1152 adults with obesity and type 2 diabetes gives the most detailed safety breakdown so far. Diarrhoea occurred in 27-34% of the retatrutide groups against 13% with placebo, and nausea in 14-28% against 8%. Two less familiar events were more frequent than with placebo: hypotension (1%, 5% and 6% across the three groups) and dysaesthesia (4%, 6% and 7%, against 1%). Permanent treatment discontinuation due to adverse events or death reached 12% and 8% in the two higher groups, compared with 4% in the lowest group and 5% with placebo; all deaths were deemed unrelated to the study intervention by the investigator [6]. The TRIUMPH-1 abstract (2339 participants) reports only that the most common adverse events were gastrointestinal [7].
Heart rate and blood pressure
A pairwise and network meta-analysis of twelve trial reports in people with obesity but without diabetes estimated a mean difference versus placebo of 3.46 for retatrutide, against 2.37 for liraglutide, 3.35 for semaglutide, 2.05 for tirzepatide and 3.47 for the class as a whole [8]. On those pooled figures, the triple agonist sits close to the class average rather than clearly above it. How glucagon-receptor activity contributes in the heart is less settled; a 2026 review argues that mouse cardiac preparations may be misleading for the human heart [9].
Blood pressure moves the other way. A meta-analysis of randomised trials estimated reductions of 6.79 mmHg systolic and 2.46 mmHg diastolic with retatrutide [10], and a broader meta-analysis of eighty-five incretin trials found the largest reductions with dual and triple agonists, without an excess of hypoglycaemia or pancreatitis across incretin therapies [11]. The TRIUMPH-2 abstract does not say whether its hypotension events reflect the same pharmacology [6].
Dysaesthesia, infections and the pancreas
Dysaesthesia, often described as burning skin sensations, has been studied mainly with marketed agents: a pharmacovigilance analysis of VigiBase and French case narratives found it more frequent at higher exposure levels and with more potent GLP-1 receptor agonists, and linked it to dysaesthesias already observed in trials of semaglutide, tirzepatide and retatrutide [12]. A 2026 letter discussed a urinary tract infection signal reported with retatrutide and whether timing helps explain it [13]. For pancreatitis, a meta-analysis of 62 GLP-1 receptor agonist trials that included retatrutide found a significantly increased overall risk (RR 1.44) that was no longer significant when stratified by background medication [14].
In post hoc kidney analyses of the two phase 2 trials, eGFR was unchanged versus placebo in type 2 diabetes and increased in obesity, while albuminuria fell at the higher levels; because most participants had normal albuminuria, the absolute change was modest [15]. A dedicated phase 2b trial in 146 adults with chronic kidney disease is measuring GFR by iohexol clearance [16].
What pooled analyses add
An early meta-analysis of three trials reported more non-severe gastrointestinal and hypersensitivity adverse events than with placebo [17], and a 2026 meta-analysis of dual and triple agonists found more adverse events leading to withdrawal (RR 1.96) but no significant difference in serious adverse events (RR 0.87) [18].
Outside the trials
Case reports describe something different from supervised trials: refractory nausea in a woman in her mid-20s after four weekly administrations of an unverified product reported to contain retatrutide, given in a wellness setting [19], and ketonaemia with acute kidney injury in a man with type 1 diabetes after an online-purchased product, complicated by concurrent Shigella infection so that causation could not be established [20]. A 2026 research letter examined self-reported adverse effects among social media users taking nonapproved retatrutide [21].
What remains open
- Duration. The longest published treatment periods are 80 weeks [6,7].
- Outcomes. Kidney and cardiovascular outcome data are still being collected [16].
- Less common events. Hypotension, dysaesthesia and infection signals need longer follow-up [6,12].
- Independence. The phase 2 and 3 reports cited here were funded by the developer [3,6].
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PubMed 36354040 · doi:10.1016/S0140-6736(22)02033-5
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PubMed 42250575 · doi:10.1016/S0140-6736(26)00967-0
- Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. PubMed 42810372 · doi:10.1016/S0140-6736(26)01861-1
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PubMed 42814954 · doi:10.1056/NEJMoa2604169
- Zhang Y, Zhang C, Gong X, et al. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. Eur J Med Res. 2026;31(1):318. PubMed 41582189 · PMC12918571 · doi:10.1186/s40001-026-03933-9
- Neumann J, Kirchefer U, Hofmann B, et al. Future GLP-1 receptor co-agonists and their cardiac effects. Naunyn Schmiedebergs Arch Pharmacol. 2026. PubMed 42768195 · doi:10.1007/s00210-026-05908-3
- Simental-Mendía LE, Barragán-Zúñiga LJ, Reyes-Avitia V. Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials. High Blood Press Cardiovasc Prev. 2026;33(5):503-516. PubMed 42371360 · doi:10.1007/s40292-026-00812-6
- Basile C, Merolla A, Mancusi C, et al. Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis. Eur J Prev Cardiol. 2026;33(7):1210-1217. PubMed 40899050 · doi:10.1093/eurjpc/zwaf560
- Laroche ML, Géniaux H, Jardou M. Dysesthesia associated with GLP-1 agonist therapies: data-mining analysis and literature review. Eur J Clin Pharmacol. 2026;82(6):154. PubMed 42168638 · PMC13194321 · doi:10.1007/s00228-026-04079-7
- Koufakis T, Argyrakopoulou G, Kokkinos A, et al. Retatrutide and the urinary tract infection signal: Is the answer hidden in timing? Eur J Intern Med. 2026:107099. PubMed 42493254 · doi:10.1016/j.ejim.2026.107099
- Wen J, Nadora D, Bernstein E, et al. Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Endocrinol Diabetes Metab. 2025;8(5):e70113. PubMed 40988099 · PMC12457091 · doi:10.1002/edm2.70113
- Heerspink HJL, Lu Z, Du Y, et al. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney Int Rep. 2025;10(6):1980-1992. PubMed 40630318 · PMC12231004 · doi:10.1016/j.ekir.2025.03.049
- Heerspink HJL, van Raalte DH, Bjornstad P, et al. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026;41(6):1058-1068. PubMed 41160422 · PMC13218929 · doi:10.1093/ndt/gfaf230
- Pasqualotto E, Ferreira ROM, Chavez MP, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024;24:100321. PubMed 39318607 · PMC11420505 · doi:10.1016/j.metop.2024.100321
- Chan ZH, Omar AS, Gill K, et al. Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. Cardiol Rev. 2026. PubMed 41711462 · doi:10.1097/CRD.0000000000001209
- Buzzi RM, Huber LC. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Rep. 2026;19(10):e276106. PubMed 42843917 · PMC13646524 · doi:10.1136/bcr-2026-276106
- Branine N. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis. Cureus. 2026;18(8):e115260. PubMed 42669023 · PMC13525912 · doi:10.7759/cureus.115260
- Sehgal NKR, Tronieri JS, Rader B, et al. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Netw Open. 2026;9(10):e2638929. PubMed 42873503 · PMC13670051 · doi:10.1001/jamanetworkopen.2026.38929